When Will Orforglipron (Foundayo) be Available in the UK?
Weight Loss
On the 10th August 2026, the Medicines and Healthcare products Regulatory Authority (MHRA) approved Foundayo, a daily oral weight loss medication containing Orforglipron.
Manufactured by Eli Lilly, this once-daily tablet offers an effective alternative to injectable GLP-1 medications without requiring strict refrigeration or fasting protocols.
Here we will explore the approval process, timeline, where the medication will be available, and the expected price for Foundayo in the UK.
What Is Foundayo?
Foundayo is a prescription-only (POM) weight loss medication belonging to the GLP-1 family of drugs.
Foundayo is a small-molecule drug formulated as a daily pill which works to:
Increase fullness - by signalling to the brain you are full, reducing appetite and food intake.
Slow stomach emptying - keeping you fuller for longer after meals.
Regulate blood sugar levels- by stimulating insulin release.
In clinical trials, patients taking the highest dose of Foundayo lost 12-15% of their starting body weight over 72 weeks.
Whilst Foundayo provides an effective oral option for patients without strict dose instructions, injection, or refrigeration, it is just one of several options already available on the market. Explore all available weight-loss medications to find the right treatment for you.
Is Foundayo Approved In The UK?
Foundayo has been approved in the UK following its regulatory review by the MHRA - the UK government body responsible for making sure medicines are safe and effective.
Can You Buy Foundayo (orforglipron) in the UK?
Yes, Foundayo has gained regulatory approval, and now available through private pharmacies. Foundayo orders can be placed at Quick Meds by filling out a consultation form. Once our prescribers have reviewed the form and assessed if you are eligible, we will despatch the medication to you as soon as the next day.
How Much Will Foundayo Cost?
Current prices of Foundayo at Quick Meds are:
Strength | Price | Pack size |
|---|---|---|
0.8 mg | £124.95 | 30 day pack |
2.5 mg | £124.95 | 30 day pack |
5.5 mg | £124.95 | 30 day pack |
9 mg | £144.95 | 30 day pack |
14.5 mg | £164.95 | 30 day pack |
17.2 mg | £174.95 | 30 day pack |
When available on the NHS, to those who are not exempt from NHS prescription charges, Foundayo will attract the standard NHS prescription charge - currently £9.90 per item.
How to Get Foundayo in the UK: NHS vs. Private Access
Foundayo is a prescription-only (POM) medication. To access treatment, patients are required to have a formal clinical assessment by a registered healthcare provider. This helps confirm suitability and safety.
Private Online Clinics and Pharmacies
The first patients to access Foundayo will be from private providers rather than through the NHS. To access treatment, patients must:
Complete an online consultation - which asks about your weight, medical history and if you take other medication.
Review and verification by a UK-based GPhC-registered prescriber.
Prescription issue and delivery.
NHS Availability
Before NHS doctors can prescribe Foundayo, the National Institute for Health and Care Excellence (NICE) must review its cost-effectiveness.
If approved by NICE, NHS access will likely be restricted to patients with the highest clinical need. This usually includes patients with a higher BMI criteria and the presence of multiple weight related co-morbidities (like type 2 diabetes or high blood pressure).
What Other Options are also Available Right Now?
For those looking to start weight loss medication immediately, there are several treatments already licensed and successfully used across the UK:
Mounjaro - a once-weekly dual GIP/GLP-1 agonist therapy showing high clinical effectiveness.
Wegovy - a once-weekly GLP-1 agonist designed for weight management.
Wegovy tablets - a once-daily tablet, suitable for those who don’t like injections.
Click here to view all available options or simply contact the team at Quick Meds to discuss what option is best for you.
Refrences
https://pmc.ncbi.nlm.nih.gov/articles/PMC12898445/
https://www.gov.uk/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf
https://www.gov.uk/guidance/national-assessment-procedure-for-medicines
https://pmc.ncbi.nlm.nih.gov/articles/PMC12898445/#sec4-ijms-27-01409
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00202-3/abstract
